icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Barcelona, Spain
13-17 April 2016
Back grey_arrow_rt.gif
 
 
 
Newest HCV Drugs at EASL
 
 
  From Jules: There are several more potent HCV therapies coming.......In addition to Gilead's Harvoni & Abbvie 3D, and the FDA approval earlier in 2016 of Merck'sElbasvir/Grazoprevir ALL in the pharmacy now...... by July 2016 the FDA is expected to approve Gilead's new Sofosbuvir+Velpatasvir; in phase 3 now is Abbvie's next generation ABT-493+ABT-530; in research alsois .....Gilead's 3 drug regimen adding 2nd generation protease inhibitor GS-9857to Sofosbuvir+Velpatasvir....and J&J's 3 drug regimen & Merck's 3 drug regimen....all pangenotypic.....and RG-101
 
ABBVIE

 
EASL:HIGH SVR RATES WITH ABT-493 + ABT-530 CO-ADMINISTERED FOR 8 WEEKS IN NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 3 INFECTION - (04/18/16)
 
EASL: HIGH EFFICACY OF ABT-493 AND ABT-530 IN HCV GENOTYPE 1-INFECTED PATIENTS WHO HAVE FAILED DIRECT-ACTING ANTIVIRAL-CONTAINING REGIMENS: THE MAGELLAN-I STUDY - (04/15/16)
 
EASL: 100% SVR12 WITH ABT-493 AND ABT-530 WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAVE HCV GENOTYPE 3-INFECTED PATIENTS WITH CIRRHOSIS - (04/19/16)
 
J&J
 
EASL:PAN-GENOTYPIC EVALUATION OF AL-335, A CLINICAL STAGE URIDINE ANALOG INHIBITOR OF HEPATITIS C VIRUS POLYMERASE - (04/18/16)
 
EASL:AL-335, A ONCE-DAILY PANGENOTYPIC NUCLEOTIDE HCV POLYMERASE INHIBITOR, DEMONSTRATES POTENT ANTIVIRAL ACTIVITY OVER 7 DAYS IN TREATMENT-NAVE GENOTYPE 1-4 PATIENTS - (04/18/16)
 
J&J will study NS5A inhibitor ACH-3102 + simeprevir + AL-335 in a 3 drug regimen.
 
GILEAD
 
EASL:Short-Duration Treatment With Sofosbuvir/Velpatasvir Plus GS-9857 in Treatment-Nave Genotype 1-6 HCV-Infected Patients With or Without Cirrhosis- (04/22/16)
 
EASL:Resistance Analysis of Genotype 1 or 3 HCV-Infected Patients Treated With Sofosbuvir/Velpatasvir + GS-9857 for 6 or 8 Weeks - (04/15/16)
 
EASL:On-Treatment HCV RNA as a Predictor of SVR12 in Patients With Genotype 1-6 HCV Infection Treated With Sofosbuvir/Velpatasvir for 12 Weeks: An Analysis of the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies- (04/26/16)
 
EASL:High Efficacy of Sofosbuvir/Velpatasvir/GS-9857 With or Without Ribavirin for 12 Weeks in Direct-Acting Antiviral-Experienced Patients With Genotype 1 HCV Infection- (04/15/16)
 
EASL:High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated With Direct-Acting Antivirals- (04/15/16)
 
MERCK
 
EASL:High Efficacy of an 8-Week, 3-Drug Regimen of MK-3682/Grazoprevir/MK-8408 in HCV Genotype 1, 2, or 3-Infected Patients: SVR24 Data from the Phase 2 C-CREST 1 and 2 Studies- (04/19/16)
 
EASL:In a 5-day Monotherapy Trial, MK-8408 Demonstrated Potent Antiviral Activity and Improved Resistance Profile in HCV Patients With Genotypes 1, 2, and 3 Infections - (04/18/16)
 
EASL:C-EDGE: HEAD 2 HEAD - Efficacy and Safety of Elbasvir/Grazoprevir versus Sofosbuvir /Pegylated Interferon/Ribavirin (PR) in Treatment-Nave and Prior PR Treatment Failure Subjects with Chronic HCV GT1 or 4 Infection- (04/15/16)
 
EASL:Final SVR24 Data from the Phase 3 C-EDGE Treatment-Nave Study of Elbasvir/Grazoprevir in Patients With Chronic HCV Genotype 1, 4, or 6 Infection - (04/29/16)
 
RG-101
 
EASL:RG-101 IN COMBINATION WITH 4 WEEKS OF ORAL DIRECT ACTING ANTIVIRAL THERAPY ACHIEVES HIGH VIROLOGIC RESPONSE RATES IN TREATMENT NAVE GENOTYPE 1 AND 4 CHRONIC HEPATITIS C PATIENTS: INTERIM RESULTS FROM A RANDOMISED, MULTI-CENTER, PHASE 2 STUDY - (04/15/16)